Terms: = Skin cancer AND TRIM33, RFG7, 51592, ENSG00000197323, Q9UPN9, TF1G, FLJ32925, TIF1G, PTC7, TIFGAMMA, TIF1GAMMA AND Treatment
9 results:
1. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review.
Kilinc OC; Ugurlu S
Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
[TBL] [Abstract] [Full Text] [Related]
2. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
Guerra NL; Matas-García A; Serra-García L; Morgado-Carrasco D; Padrosa J; Aldecoa I; Duque Y; Casal-Dominguez M; Muñoz-Braceras S; Aranega R; Moreno-Lozano P; Cantó-Santos J; Garrabou G; Ruiz-Ortiz E; Trallero-Araguas E; Selva-O'Callaghan A; Grau JM; Puig S; Torres-Ruiz J; Mammen AL; Fernandez IP; Milisenda JC
Autoimmun Rev; 2023 Aug; 22(8):103375. PubMed ID: 37321468
[TBL] [Abstract] [Full Text] [Related]
3. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract] [Full Text] [Related]
4. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract] [Full Text] [Related]
5. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract] [Full Text] [Related]
6. Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
Wolstencroft PW; Casciola-Rosen L; Fiorentino DF
JAMA Dermatol; 2018 Oct; 154(10):1199-1203. PubMed ID: 30140893
[TBL] [Abstract] [Full Text] [Related]
7. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
Kubeček O; Soukup T; Paulík A; Kopecký J
BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
[TBL] [Abstract] [Full Text] [Related]
8. Advances in serological diagnostics of inflammatory myopathies.
Benveniste O; Stenzel W; Allenbach Y
Curr Opin Neurol; 2016 Oct; 29(5):662-73. PubMed ID: 27538058
[TBL] [Abstract] [Full Text] [Related]
9. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract] [Full Text] [Related]
